scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.LPM.2014.03.007 |
P698 | PubMed publication ID | 24855048 |
P50 | author | Nathalie Costedoat-Chalumeau | Q47262464 |
P2093 | author name string | Nathalie Morel | |
Véronique Le Guern | |||
Bertrand Dunogué | |||
Gaëlle Guettrot-Imbert | |||
P433 | issue | 6 Pt 2 | |
P921 | main subject | hydroxychloroquine | Q421094 |
P304 | page(s) | e167-80 | |
P577 | publication date | 2014-05-19 | |
P1433 | published in | Presse médicale | Q127260618 |
P1476 | title | Hydroxychloroquine: a multifaceted treatment in lupus | |
P478 | volume | 43 |
Q40795030 | Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification |
Q28069143 | Anti-inflammatory and Immunomodulatory Effects of Antibiotics and Their Use in Dermatology |
Q33650548 | Association between use of disease-modifying antirheumatic drugs and diabetes in patients with ankylosing spondylitis, rheumatoid arthritis, or psoriasis/psoriatic arthritis: a nationwide, population-based cohort study of 84,989 patients |
Q26999216 | Autophagy in cancer |
Q100153806 | C-ter TLR7 dimer binds HCQ |
Q100153807 | C-ter TLR9 dimer binds HCQ |
Q38897521 | CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency |
Q99413596 | COVID-19 in systemic lupus erythematosus: data from a survey on 417 patients |
Q38360827 | Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases |
Q55208303 | Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis. |
Q94685368 | Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data |
Q47441501 | Compliance and persistence with hydroxychloroquine in South Korean patients with systemic lupus erythematosus. |
Q97644054 | Coronavirus Disease 2019 (COVID-19) and Transplantation: Pharmacotherapeutic Management of Immunosuppression Regimen |
Q54218397 | Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. |
Q33422958 | Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus |
Q38776952 | Development and validation of a clinical HPLC method for the quantification of hydroxychloroquine and its metabolites in whole blood |
Q40556363 | Disease Activity During Pregnancy and the First Year Postpartum in Women With Systemic Lupus Erythematosus |
Q38806513 | Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies |
Q48120219 | Early cutaneous eruptions after oral hydroxychloroquine in a lupus erythematosus patient: A case report and review of the published work |
Q64118839 | Effect of Hydroxychloroquine and Anti-BDCA2 mAb Treatment on pDC IFNα Production From Patients Affected With Cutaneous Lupus Erythematosus |
Q90415013 | Flares in systemic lupus erythematosus: diagnosis, risk factors and preventive strategies |
Q38560780 | Genomics of Immune Diseases and New Therapies |
Q47842487 | Health status and concomitant prescription of immunosuppressants are risk factors for hydroxychloroquine non-adherence in systemic lupus patients with prolonged inactive disease. |
Q97075375 | Hippocampal Atrophy in Systemic Lupus Erythematosus Patients without Major Neuropsychiatric Manifestations |
Q93213302 | Hydroxychloroquine and "off-label" utilization in the treatment of oral conditions |
Q95633060 | Hydroxychloroquine effects on psoriasis: a systematic review and a cautionary note for COVID-19 treatment |
Q41915768 | Hydroxychloroquine hindering of diabetic isletopathy carries its signature on the inflammatory cytokines. |
Q39031764 | Hydroxychloroquine in systemic lupus erythematosus (SLE). |
Q99726452 | Hydroxychloroquine levels in patients with systemic lupus erythematosus: whole blood is preferable but serum levels also detect non-adherence |
Q39172826 | Hydroxychloroquine retinopathy |
Q47396929 | Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome? |
Q38883883 | Immunomodulators in SLE: Clinical evidence and immunologic actions |
Q58604686 | Intrauterine fetal deaths related to antiphospholipid syndrome: a descriptive study of 65 women |
Q97533087 | Is hydroxychloroquine beneficial for COVID-19 patients? |
Q52626305 | Isolated acute lupus pneumonitis as the initial presentation of systemic lupus erythematosus in an 8-year-old girl. |
Q40725518 | Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: a long-term retrospective cohort study |
Q64084551 | Lysosomal pH Is Regulated in a Sex Dependent Manner in Immune Cells Expressing |
Q38998709 | NETopathies? Unraveling the Dark Side of Old Diseases through Neutrophils |
Q59808159 | Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort |
Q96686028 | Prevalence of hydroxychloroquine retinopathy using 2018 Royal College of Ophthalmologists diagnostic criteria |
Q42043474 | Pro-inflammatory Ca++-activated K+ channels are inhibited by hydroxychloroquine |
Q38773552 | Refractory pulmonary sarcoidosis - proposal of a definition and recommendations for the diagnostic and therapeutic approach |
Q35877606 | Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis |
Q38431886 | Stem cell therapies for systemic lupus erythematosus: current progress and established evidence |
Q89784271 | Systemic lupus erythematosus aggravates atherosclerosis by promoting IgG deposition and inflammatory cell imbalance |
Q35530248 | Systemic lupus erythematosus and thrombosis |
Q58698067 | Up-Regulation of TLR7-Mediated IFN-α Production by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus |
Q89338390 | [Lupus nephritis] |
Q89894663 | [Tapering and termination of immunosuppressive therapy : Systemic lupus erythematosus] |
Search more.